TG Therapeutics (NASDAQ:TGTX) Reaches New 1-Year High - Time to Buy?

Key Points

• 52‑week high: TG Therapeutics hit a new 52‑week intraday high of $41.24 and last traded around $39.13 on ~1.18M shares, with a market cap of $5.91B and 50/200‑day moving averages near $32.24/$31.49.
• Analyst sentiment: The consensus is a Moderate Buy with an average price target of $50.00 (1 Strong Buy, 3 Buy, 2 Hold, 1 Sell), though firms differ on targets and ratings (e.g., JPMorgan cut its PT to $46 while Goldman raised its PT to $39).
• Quarterly results: TG missed EPS expectations ($0.14 vs. $0.35) but reported revenue of $192.57M in line with estimates and up 78% year‑over‑year, alongside unusually high reported ROE and net margin figures.

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $41.24 and last traded at $39.1290, with a volume of 1179057 shares changing hands. The stock had previously closed at $36.10.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. JPMorgan Chase & Co. cut their price target on TG Therapeutics from $49.00 to $46.00 and set an "overweight" rating for the company in a report on Monday, February 2nd. Wall Street Zen cut TG Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, February 14th. The Goldman Sachs Group increased their price objective on TG Therapeutics from $37.00 to $39.00 and gave the stock a "neutral" rating in a research report on Thursday, January 15th. Cantor Fitzgerald reiterated an "overweight" rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. Finally, Weiss Ratings upgraded TG Therapeutics from a "hold (c)" rating to a "hold (c+)" rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $50.00.

TG Therapeutics Stock Performance

The company has a fifty day moving average price of $32.24 and a 200 day moving average price of $31.49. The stock has a market cap of $5.91 billion, a P/E ratio of 13.90 and a beta of 1.68. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.10 and a quick ratio of 3.29.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.35 by ($0.21). TG Therapeutics had a return on equity of 101.12% and a net margin of 72.56%.The company had revenue of $192.57 million for the quarter, compared to the consensus estimate of $192.15 million. During the same quarter last year, the company posted $0.15 EPS. The company's quarterly revenue was up 78.0% compared to the same quarter last year. On average, equities analysts expect that TG Therapeutics, Inc. will post 1.32 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TGTX. Bessemer Group Inc. increased its stake in TG Therapeutics by 0.5% in the 1st quarter. Bessemer Group Inc. now owns 132,555 shares of the biopharmaceutical company's stock worth $4,403,000 after acquiring an additional 603 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in TG Therapeutics by 10.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 18,887 shares of the biopharmaceutical company's stock worth $634,000 after acquiring an additional 1,769 shares during the last quarter. Sanctuary Advisors LLC bought a new position in TG Therapeutics during the 1st quarter worth approximately $256,000. Bleakley Financial Group LLC bought a new position in TG Therapeutics during the 1st quarter worth approximately $386,000. Finally, Fifth Third Bancorp lifted its holdings in TG Therapeutics by 4,186.0% in the 1st quarter. Fifth Third Bancorp now owns 31,759 shares of the biopharmaceutical company's stock worth $1,055,000 after buying an additional 31,018 shares during the period. Hedge funds and other institutional investors own 58.58% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company's research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.